# Niuruite Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/niuruite-medical

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.nrtmedtech.com
- Total disclosed funding: $332M
- Latest round: Series E (Apr 3, 2026)
- Investors on record: 32

## About

Established in 2016 and headquartered in Chengdu, China, Chengdu Niuruite Medical Technology Co., Ltd., trading as Niuruite Medical, was founded by a team of nuclear industry scientists including former senior members of the China National Nuclear Corporation. In 2020, the company was recognized as a “quasi-unicorn enterprise.”  In April 2026, Niuruite Medical raised CNY 1 billion in series E co-led by Shanghai STVC Group, Shanghai Guoxin Venture Capital Investment, Neovision Capital, with participation from Shanghai STVC Group, Yuekai Capital, Linchuang Capital, CAS Investment Management, Shanghai Growth Investment, CoStone Capital, Pudong Venture Capital, Efung Capital and STAR Capital, Zhongqi Capital, Sichuan Venture Capital, and other investors.
Niuruite Medical develops and produces a range of radiopharmaceuticals and isotopes used in the diagnosis and treatment of malignant tumors. Its portfolio includes radioactive glass microspheres, radioactive embolization microspheres, and various nuclides such as Ge-68 and Ac-225. The company operates China’s first commercial 30MeV IKON proton accelerator and is advancing multiple clinical-stage nuclear drug candidates, including NRT6003 (for liver cancer) and NRT6008 (for pancreatic cancer).

The company generates revenue from sales of medical isotopes, radiopharmaceutical products, and related technical consulting services to hospitals, research institutes, and pharmaceutical companies.

The series E funds raised will be primarily used for the clinical development of the core pipeline of radiopharmaceuticals, the research, development, production and market construction of medical isotopes, etc., in order to consolidate the company's leading position in the field of domestic medical isotopes and radiopharmaceuticals.

## Funding rounds

- Series E, Apr 3, 2026, $145M — STAR Capital, Shanghai STVC Group, CAS Investment Management, CoStone Capital, Efung Capital, Neovision Capital, Shanghai Guoxin Venture Capital Investment, Linchuang Capital, Sichuan Venture Capital, Shanghai Growth Investment, Pudong Venture Capital, Zhongqi  Capital, Yuekai Capital
- Series D, Oct 10, 2025, $112M — China International Capital Corporation, PICC Capital Equity Investment, Fujian Venture, Shenzhen Capital Real Estate Fund, Star Capital, Chengdu Airport Innovation and Entrepreneurship Investment, Leshan High-Tech Investment Development (Group), Hunan Chasing Fund Management, Zhongqi  Capital, Kaiheng Capital, China National Nuclear Corporation Capital
- Series C, Mar 14, 2024, $42M — Fujian Venture, Neovision Capital, Star Capital, Sichuan Venture Capital, Chengdu Science and Technology Innovation Investment Group, BIO-TOWN Capital
- Series B, Jul 17, 2019, $17M — BTG, Ruiying Capital
- Series A, Feb 11, 2018, $16M — Apex Capital, Beida Fund, Ruiying Capital, DEMO INVESTMENT, Hangzhou Gupu Asset Management, Foot, Thinkfund Investment

## Investors

- Apex Capital — Series A
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series A
- Ruiying Capital (https://capitalatlas.ai/funds/ruiying-capital) — Series A, Series B
- DEMO INVESTMENT — Series A
- Hangzhou Gupu Asset Management — Series A
- Foot — Series A
- Thinkfund Investment (https://capitalatlas.ai/funds/thinkfund-investment) — Series A
- BTG — Series B
- Fujian Venture (https://capitalatlas.ai/funds/fujian-venture) — Series C, Series D
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series C, Series E
- Star Capital — Series C, Series D, Series E
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series C, Series E
- Chengdu Science and Technology Innovation Investment Group — Series C
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series D
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series D
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series D
- Chengdu Airport Innovation and Entrepreneurship Investment — Series D
- Leshan High-Tech Investment Development (Group) — Series D
- Hunan Chasing Fund Management (https://capitalatlas.ai/funds/hunan-chasing-fund-management) — Series D
- Zhongqi  Capital (https://capitalatlas.ai/funds/zhongqi-capital) — Series D, Series E
- Kaiheng Capital (https://capitalatlas.ai/funds/kaiheng-capital) — Series D
- China National Nuclear Corporation Capital — Series D
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series E
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series E
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series E
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series E
- Shanghai Guoxin Venture Capital Investment — Series E
- Linchuang Capital (https://capitalatlas.ai/funds/linchuang-capital) — Series E
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series E
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series E
- Yuekai Capital (https://capitalatlas.ai/funds/yuekai-capital) — Series E